Takeda

Real World Study of Rixubis in Patients with Hemophilia B

MedicalResearch.com Interview with:

TakedaDr. med. Wolfhard Erdlenbruch, M.D.
Vice President
Head of Global Medical Affairs Hematology

MedicalResearch.com: What is the background for this study?

Dr. med. Wolfhard Erdlenbruch

Dr. Erdlenbruch

Response: At the World Federation of Hemophilia Virtual Summit 2020 (WFH 2020), results were presented from a real-world, post-marketing surveillance study aimed to evaluate the safety and effectiveness of RIXUBIS® in adult and pediatric patients with hemophilia B in South Korea, entitled “Safety and Effectiveness of Rixubis in Patients with Hemophilia B in South Korea: A Real-World, Prospective, Post-marketing Surveillance Study”.

Data from the study demonstrate the safety and efficacy profile of RIXUBIS® for treatment of bleeds, perioperative/surgery, and prophylaxis in adult and pediatric patients with hemophilia B in the real-world setting in South Korea. The study showed that 86.6% (123/142) of hemostatic effectiveness assessments for RIXUBIS® were reported as good or excellent, and of the 11 adverse events reported, all were mild in severity, with 10 resolved/recovered events not related to RIXUBIS®, and one event (inhibitory antibody development) unconfirmed.1

RIXUBIS® [Nonacog gamma, recombinant FIX concentrate] is a recombinant coagulation factor IX product, indicated for the control and prevention of bleeding episodes in patients with hemophilia B.


MedicalResearch.com: What should readers take away from your report?

Response: I’m glad that RIXUBIS® has a demonstrated safety profile and effectiveness for the treatment of bleeds, perioperative/surgery, and prophylaxis in adult and pediatric patients with hemophilia B in the real-world setting in South Korea. These results are consistent with data gathered from other studies worldwide, and I hope the study results will benefit patients with hemophilia B by providing them with a treatment option that is safe and effective. 

MedicalResearch.com: What recommendations do you have for future research as a result of this work?

Response: I hope we will continue to generate more real world data supporting the use of RIXUBIS® as a standard of treatment in hemophilia B.

MedicalResearch.com: Is there anything else you would like to add?

Response: RIXUBIS® is an injectable medicine used to replace clotting factor IX that is missing in adults and children with hemophilia B, marketed by Baxalta US Inc., a member of the Takeda group of companies.

For more information, please refer to the RIXUBIS® Summary of Product Characteristics here. 

For US specific safety information, please refer to the RIXUBIS® US Prescribing Information here. 

Reference:
1. WFH 2020 Virtual Summit. iPoster MED-PO-018. Safety and Effectiveness of Rixubis in Patients with Hemophilia B in South Korea: A Real-World, Prospective, Post-marketing Surveillance Study.

JOIN OUR EMAIL LIST

We respect your privacy and will never share your details.

Jun 25, 2020 @ 5:02 pm 

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, endorse, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.